Back to top
more

Momenta Pharmaceuticals, Inc. (MNTA)

(Delayed Data from NSDQ)

$14.57 USD

14.57
596,216

+0.53 (3.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.58 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Why Is Momenta (MNTA) Up 86.9% Since Last Earnings Report?

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunovant Up on Positive Data From Myasthenia Gravis Study

Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.

Sweta Killa headshot

ETFs in Focus on Momenta Buyout Deal With JNJ

A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.

J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence

J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.

Momenta Surges on Acquisition Deal With Johnson & Johnson

Momenta (MNTA) soars on the announcement of being acquired by Johnson & Johnson for $6.5 billion.

Company News for Aug 20, 2020

Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.

S&P 500 Records a Fresh All-Time High

S&P 500 Records a Fresh All-Time High.

Pre-Markets Mixed Following S&P 500's Fresh High, Strong Earnings

Market participants enjoyed an astonishing 54.7% rally of the broad-market S&P 500 Index since its crash on Mar 23.

Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Tops Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Ranked Momentum Stocks to Buy for July 6th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 6th.

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

Momenta (MNTA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Nalak Das headshot

5 Top Momentum Stocks of June Amid Resurgence of Coronavirus

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Momenta Pharmaceuticals, Inc. (MNTA) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).

Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

Momenta (MNTA) Up on Positive Data From Generalized MG Drug

Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.

Company News for Jun 16, 2020

Companies in the news are: JKS, MNTA, CAI, CATM

Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.